Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Tensions Flare at Chuikyo over Premiums for Generic Dispensing
September 16, 2025
- Motegi Calls for Lowering Generic Prices by Consolidation: LDP Race
September 11, 2025
- Lawmakers Urge Chuikyo to Respect Public-Private Council Views
September 11, 2025
- MHLW Panel Urges Tighter Scrutiny of GLP-1 “Weight Loss” Ads
September 11, 2025
- JPMA Pushes for Mandatory Collection of Medical Data, JMA Fires Back
September 11, 2025
- Reblozyl Faces Price Cut after Cost-Effectiveness Assessment
September 11, 2025
- Generics to Be Exempt from Tariffs under US-Japan Deal: Govt Officials
September 10, 2025
- Label Revisions Ordered for Antihypertensives, Adalimumab, I/O Meds, and More
September 10, 2025
- Japan Panel Approves 5 COVID Vaccines for NIP Use from October
September 9, 2025
- MHLW Seeks to Raise Quality of Prefectural Generic GMP Inspections
September 8, 2025
- MHLW Panel Backs Draft ARI Prevention Guidelines, Due Out November
September 5, 2025
- Japan Kicks Off Debate on Medical Data Use Framework, Eyes 2027 Legislation
September 4, 2025
- MHLW Seeks Sponsor for Drug Loss Product Trifarotene
September 4, 2025
- Japan Govt Council Gathers Views to Shape National MCM Strategy
September 4, 2025
- Japan Panel Supports Plan to Prioritize MCM Development by Need and Feasibility
September 4, 2025
- Generics Surge in FY2024 on New Out-of-Pocket Rule for Long-listed Drugs
September 3, 2025
- Pharma Groups Press Pricing Reform at First Public-Private WG Meeting
September 2, 2025
- Japan Panel Clears Izervay, Nexletol for Approval; Eylea Biosimilars Edge Ahead Too
September 1, 2025
- METI Proposes “Bold Investment” Tax Breaks in FY2026 Request
September 1, 2025
- Japan Panel Green Lights Nonprescription Switch of Morning-After Pill
September 1, 2025
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…